Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia
-
- STATUS
- Recruiting
-
- End date
- Dec 25, 2022
-
- participants needed
- 40
-
- sponsor
- University Hospital, Montpellier
Summary
Background. Cancer is the leading cause of death by disease in children. Most pediatric tumors differ from adult tumors in terms of biological and clinical characteristics. In children, the part of genetic determinism could be higher since the role of environmental factors may be less pronounced than in adults and that a young age at onset is a main feature of genetic cancer predisposition. Recent studies suggested that a number of genetic predisposition remains to be characterized.
Methods. Trio-Based whole exome sequencing of germline DNA from patients (children and adults diagnosed with cancers between 0 and 17 years) and parents will be performed prospectively in a multicentric study including 40 unselected cases of malignant tumor. Participating hospitals will include the CHU of Montpellier, the CHU de Nice and the AP-HP. Tumor analysis will include whole exome analysis and transcriptome for the identification of therapeutic target and contribute to confirm potential link between constitutive mutations and tumor phenotype (such as loss of expression, loss of heterozygosity).
Perspectives. This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.
Details
| Condition | Hematologic Malignancy, Blood Cancer, Hematologic Cancer, Hematologic Neoplasms, Hereditary Cancer, Familial Cancer, Blood Cancer, Hematologic Cancer, Hematologic Neoplasms, Pediatric Tumor, Solid Tumor, Childhood, Solid Tumor, Childhood, hematological malignancy, hematologic malignancies, hematological tumor, haematological malignancy, hematological malignancies, Solid Tumor, Childhood, Solid Tumor, Childhood, Solid Tumor, Childhood |
|---|---|
| Treatment | Exome sequencing in pediatrics cancers |
| Clinical Study Identifier | NCT04471961 |
| Sponsor | University Hospital, Montpellier |
| Last Modified on | 25 March 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer